Penumbra Sale To Boston Scientific Puts Focus On Deal Terms And Future

Simply Wall St.03-04

Penumbra (NYSE:PEN) has entered into a definitive agreement to be acquired by Boston Scientific. The all cash transaction values Penumbra at approximately US$14.5b. The deal is subject to approval by ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2616589455?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163","is_english":true,"pubTime":"2026-03-04 13:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616589455","market":"nz","top_or_hot":-1,"title":"Penumbra Sale To Boston Scientific Puts Focus On Deal Terms And Future","media":"Simply Wall St.","content":"<div>\n<p>Penumbra (NYSE:PEN) has entered into a definitive agreement to be acquired by Boston Scientific. The all cash transaction values Penumbra at approximately US$14.5b. The deal is subject to approval by ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-pen/penumbra/news/penumbra-sale-to-boston-scientific-puts-focus-on-deal-terms\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Penumbra Sale To Boston Scientific Puts Focus On Deal Terms And Future</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPenumbra Sale To Boston Scientific Puts Focus On Deal Terms And Future\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-04 13:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-pen/penumbra/news/penumbra-sale-to-boston-scientific-puts-focus-on-deal-terms><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Penumbra (NYSE:PEN) has entered into a definitive agreement to be acquired by Boston Scientific. The all cash transaction values Penumbra at approximately US$14.5b. The deal is subject to approval by ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-pen/penumbra/news/penumbra-sale-to-boston-scientific-puts-focus-on-deal-terms\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1791710400.SGD","symbol_name":"Fidelity Global Demographics A-ACC-SGD","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-pen/penumbra/news/penumbra-sale-to-boston-scientific-puts-focus-on-deal-terms","article_id":"2616589455","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-pen/penumbra/news/penumbra-sale-to-boston-scientific-puts-focus-on-deal-terms","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2616589455","pubTimestamp":1772602307,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Penumbra (NYSE:PEN) has entered into a definitive agreement to be acquired by Boston Scientific.\nThe all cash transaction values Penumbra at approximately US$14.5b.\nThe deal is subject to approval by Penumbra shareholders and other customary closing conditions.\n\nPenumbra focuses on medical devices for neurovascular and peripheral vascular conditions, areas that continue to attract attention as populations age and care standards evolve. Boston Scientific’s agreement to acquire NYSE:PEN adds...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU0011850046.USD":"贝莱德全球长线股票 A2 USD","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0345769128.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) ACC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","BSX":"波士顿科学","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","BK4581":"高盛持仓","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU0345769631.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) INC","LU0251132253.USD":"FIDELITY FUNDS  GLOBAL THEMATIC OPPORTUNITIES \"A\" (USD) ACC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU1548497426.USD":"安联环球人工智能AT Acc","LU2244417387.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) ACC","PEN":"Penumbra Inc","BK4585":"ETF&股票定投概念","LU2506952097.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (USDHDG) ACC","LU0823417737.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) INC","LU2506951958.HKD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (HKDHDG) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","BK4082":"医疗保健设备","LU2506952170.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (USDHDG) INC","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU0238689110.USD":"贝莱德环球动力股票基金","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0353189763.USD":"ALLSPRING  US ALL CAP GROWTH FUND \"I\" (USD) ACC"},"translate_title":"Penumbra出售给波士顿科学公司将重点放在交易条款和未来上","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BSX":1.5,"PEN":1.5},"content_text":"Penumbra (NYSE:PEN) has entered into a definitive agreement to be acquired by Boston Scientific. The all cash transaction values Penumbra at approximately US$14.5b. The deal is subject to approval by Penumbra shareholders and other customary closing conditions.  Penumbra focuses on medical devices for neurovascular and peripheral vascular conditions, areas that continue to attract attention as populations age and care standards evolve. Boston Scientific’s agreement to acquire NYSE:PEN adds another large transaction to the medical device sector, where bigger players frequently look to add specialized product lines and clinical capabilities through acquisitions. For you as an investor, a pending cash acquisition at a set headline value often shifts attention toward deal terms, timing, and closing risks rather than standalone prospects. It also raises questions about how the combined product portfolio and customer relationships could change over time once integration plans are finalized and, if approved, the transaction eventually closes. Stay updated on the most important news stories for Penumbra by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Penumbra. NYSE:PEN Earnings & Revenue Growth as at Mar 2026 2 things going right for Penumbra that this headline doesn't cover. This deal lands just after a year where Penumbra reported higher sales and earnings for both the fourth quarter and full year 2025. For some investors, the US$14.5b all cash headline value effectively caps the near term upside in Penumbra’s standalone story and instead puts the focus on how reliable the takeover consideration looks compared with their own expectations for the business if it had remained independent. AdvertisementHow This Fits Into The Penumbra Narrative  The takeover proposal aligns with the narrative that Penumbra’s therapies and global reach have meaningful room to expand, since Boston Scientific is a large medtech peer with an established presence alongside companies such as Medtronic and Abbott. The earlier narrative leaned on future clinical catalysts and product launches driving long term earnings growth, while the proposed acquisition shifts the emphasis to a one time realization of value rather than that longer multi year path. The cash acquisition structure, potential integration choices, and the prospect of Penumbra becoming a wholly owned subsidiary were not central to the earlier storyline, so investors may want to reassess how those elements change the risk and reward profile that was originally outlined.  Knowing what a company is worth starts with understanding its story.\n Check out one of the top narratives in the Simply Wall St Community for Penumbra to help decide what it's worth to you. The Risks and Rewards Investors Should Consider  ⚠️ The transaction still depends on Penumbra shareholder approval and regulatory clearances, so there is always a chance of delay or that the deal terms are revisited. ⚠️ If the acquisition closes and Penumbra is delisted, shareholders who prefer direct exposure to a focused neurovascular and vascular device company may instead hold a larger diversified player, which comes with a different risk profile. 🎁 The proposed cash acquisition provides clarity on an exit value that investors can compare to their own view of Penumbra’s prospects based on its recent earnings track record. 🎁 Being part of Boston Scientific could give Penumbra’s product portfolio access to broader distribution and customer relationships, which some investors may see as supportive for the combined company’s competitive position against peers.  What To Watch Going Forward From here, the key things to follow are formal communications around the merger timeline, any updates on regulatory reviews, and the details of the shareholder vote. You may also want to track how both companies describe integration priorities, especially for Penumbra’s neurovascular and peripheral vascular product lines, and whether those plans affect expectations for product development or commercial roll out. Finally, keep an eye on any changes to the transaction structure or competing proposals, as these can directly affect the risk and potential payoff for existing Penumbra shareholders. To ensure you're always in the loop on how the latest news impacts the investment narrative for Penumbra, head to the\n community page for Penumbra to never miss an update on the top community narratives.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2616589455","isCrawlerRequest":true}